Study shows first-of-its kind gene therapy can restore vision to people with an inherited retinal disorder
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.
Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.
Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.
Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.
LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient’s eyes.
Treatment doesn’t restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.
More than 200 patients with LCA have participated in gene therapy trials since 2007.
However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn’t obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.
The Latest on: Gene therapy
- Global Cancer Gene Therapy Market Opportunity Assessment|Key Players: Sibiono Genetech, Human Stem Cell Institute, Altor Bioscience Corporation, Amgen on October 6, 2018 at 3:22 am
Global Cancer Gene Therapy to exceed USD 4 billion by 2024 as per a new research report. Robust research and development in the field of cancer gene therapy aimed at finding cure for rare genetic canc... […]
- Advances in gene therapy for erectile dysfunction: promises and challenges. on October 6, 2018 at 12:00 am
Erectile dysfunction (ED) is a major health problem in men. Over the past few decades, oral phosphodiesterase type 5 (PDE5) inhibitors have been adopted as the recommended strategy to treat ED in the ... […]
- With Orchard’s IPO, GSK’s Old Gene Therapy Biz Gets a Wall Street Test on October 5, 2018 at 6:24 pm
GlaxoSmithKline’s former gene therapy portfolio is headed to Wall Street—in the hands of Orchard Therapeutics. The London, Boston, and San Francisco, CA, company has filed for an IPO, aiming to back b... […]
- This Biotech Stock Popped On 'Striking' Data For Gene Therapy on October 5, 2018 at 11:11 am
Audentes Therapeutics (BOLD) stock popped Friday after the biotech company announced what it termed "striking" results for its gene therapy in a muscle disease. The biotech company tested its gene the... […]
- Surprise! Bluebird Bio’s beta thalassemia gene therapy is already under review in Europe on October 5, 2018 at 2:11 am
Bluebird Bio (BLUE) is surprising investors Friday with some unexpectedly good news out of Europe. A marketing application covering the Cambridge, Mass., biotech’s gene therapy for beta thalassemia wa... […]
- Sarepta’s Gene Therapy for Rare Muscle Disease Impresses Wall Street in Early Study on October 4, 2018 at 6:19 am
Sarepta Therapeutics Inc. impressed Wall Street yet again with its updated early-stage data for its Duchenne muscular dystrophy gene therapy. Analysts broadly applauded the results and viewed the pres... […]
- Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy on October 3, 2018 at 2:30 pm
An experimental gene therapy dramatically improved the ability of a young boy with Duchenne muscular dystrophy to rise from the ground or climb stairs, repeating and improving on results seen in three ... […]
- Hop, skip, jump. Sarepta’s Duchenne gene therapy delivers early muscle function improvements on October 3, 2018 at 2:21 pm
In a clinical trial earlier this year, an experimental gene therapy for Duchenne muscular dystrophy, licensed to Sarepta Therapeutics (SRPT), produced large increases in a crucial muscle protein norma... […]
- Success in animal study points to a potentially safer, more reliable avenue for delivering gene therapy to human patients on October 3, 2018 at 10:40 am
Fixing or replacing faulty genes has emerged as a key to unlocking cures for numerous devastating diseases. But if the new engineered genes can't find their way into the patient's genomic sequence, th... […]
- Nationwide Children's made nearly $5M on gene therapy spinoff – and a software spinoff just raised $3M on October 3, 2018 at 10:00 am
Nationwide Children's Hospital netted $4.7 million on the recent acquisition of a gene therapy spinoff, with a chance of future revenue streams, putting it on track for about $6.5 million in tech lice... […]
via Google News and Bing News